Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
R&D
Biotech
Amgen axes an obesity asset, zooms in on MariTide
Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide.
Gabrielle Masson
May 2, 2024 6:16pm
Gilead gives up on $4.9B antibody magrolimab
Apr 26, 2024 10:04am
BioMarin axes 4 candidates, centers R&D around 3 assets
Apr 25, 2024 10:10am
Sanofi shrinks $6B biobucks deal with IGM
Apr 17, 2024 11:05am
Pfizer closes R&D unit that spawned $7.1B anti-TL1A med
Apr 17, 2024 7:00am
Top 10 pharma R&D budgets in 2023
Mar 18, 2024 5:00am